MJNE Stock Overview
MJ Holdings, Inc., a cannabis holding company, engages in cultivation management, asset, and infrastructure development business in Nevada.
MJ Holdings Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.25|
|52 Week High||US$0.48|
|52 Week Low||US$0.14|
|1 Month Change||-10.55%|
|3 Month Change||9.09%|
|1 Year Change||-29.71%|
|3 Year Change||-48.75%|
|5 Year Change||n/a|
|Change since IPO||-89.35%|
Recent News & Updates
|MJNE||US Pharmaceuticals||US Market|
Return vs Industry: MJNE underperformed the US Pharmaceuticals industry which returned 1.9% over the past year.
Return vs Market: MJNE underperformed the US Market which returned -12.9% over the past year.
|MJNE Average Weekly Movement||13.2%|
|Pharmaceuticals Industry Average Movement||11.8%|
|Market Average Movement||7.9%|
|10% most volatile stocks in US Market||17.1%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: MJNE is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: MJNE's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
MJ Holdings, Inc., a cannabis holding company, engages in cultivation management, asset, and infrastructure development business in Nevada. It is also involved in production of cannabis related products; and provision of management services, dispensaries, and consulting services. The company was incorporated in 2006 and is based in Las Vegas, Nevada.
MJ Holdings Fundamentals Summary
|MJNE fundamental statistics|
Is MJNE overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MJNE income statement (TTM)|
|Cost of Revenue||US$341.63k|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.068|
|Net Profit Margin||16,089.40%|
How did MJNE perform over the long term?See historical performance and comparison
Is MJNE undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MJNE?
Other financial metrics that can be useful for relative valuation.
|What is MJNE's n/a Ratio?|
Price to Book Ratio vs Peers
How does MJNE's PB Ratio compare to its peers?
|MJNE PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
TTNP Titan Pharmaceuticals
VRPX Virpax Pharmaceuticals
GRAY Graybug Vision
MJNE MJ Holdings
Price-To-Book vs Peers: MJNE is expensive based on its Price-To-Book Ratio (9x) compared to the peer average (1.2x).
Price to Earnings Ratio vs Industry
How does MJNE's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?
Price-To-Book vs Industry: MJNE is expensive based on its Price-To-Book Ratio (9x) compared to the US Pharmaceuticals industry average (2x)
Price to Book Ratio vs Fair Ratio
What is MJNE's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||9x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate MJNE's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of MJNE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate MJNE's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate MJNE's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is MJ Holdings forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as MJ Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Take a look at our analysis of MJNE’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access MJ Holdings's filings and announcements here.
How has MJ Holdings performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MJNE is currently unprofitable.
Growing Profit Margin: MJNE is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MJNE is unprofitable, but has reduced losses over the past 5 years at a rate of 22.6% per year.
Accelerating Growth: Unable to compare MJNE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MJNE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (15.5%).
Return on Equity
High ROE: MJNE has a negative Return on Equity (-263.88%), as it is currently unprofitable.
Discover strong past performing companies
How is MJ Holdings's financial position?
Financial Health Score3/6
Financial Health Score 3/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: MJNE's short term assets ($4.0M) do not cover its short term liabilities ($4.8M).
Long Term Liabilities: MJNE's short term assets ($4.0M) exceed its long term liabilities ($686.3K).
Debt to Equity History and Analysis
Debt Level: MJNE has more cash than its total debt.
Reducing Debt: MJNE's debt to equity ratio has increased from 47.9% to 49.7% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MJNE has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: MJNE has less than a year of cash runway if free cash flow continues to reduce at historical rates of 4.3% each year
Discover healthy companies
What is MJ Holdings's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MJNE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MJNE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MJNE's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MJNE's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as MJNE has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Roger Bloss (65 yo)
Mr. Roger J. Bloss serves as the Director at MJ Holdings, Inc. since April 1, 2019 and serves as its Chief Executive Officer since October 26, 2021 and also served as its Interim Chief Executive Officer si...
CEO Compensation Analysis
Compensation vs Market: Roger's total compensation ($USD184.62K) is below average for companies of similar size in the US market ($USD767.73K).
Compensation vs Earnings: Roger's compensation has been consistent with company performance over the past year.
Experienced Board: MJNE's board of directors are considered experienced (3.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.7%.
MJ Holdings, Inc.'s employee growth, exchange listings and data sources
- Name: MJ Holdings, Inc.
- Ticker: MJNE
- Exchange: OTCPK
- Founded: 2006
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$19.526m
- Shares outstanding: 79.37m
- Website: https://www.mjholdingsinc.com
Number of Employees
- MJ Holdings, Inc.
- 2580 S Sorrel St
- Las Vegas
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/07 00:00|
|End of Day Share Price||2022/08/05 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.